FDA Extends Review Of Wyeth/Progenics Methylnaltrexone NDA Until April
This article was originally published in Pharmaceutical Approvals Monthly
FDA has pushed back the action date on Wyeth and Progenics' NDA for the subcutaneous formulation of methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, until April 30, the companies announced Jan. 10
You may also be interested in...
Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.